Trial Profile
A study to investigate efficacy of intravitreal ranibizumab for treating choroidal neovascularization secondary to pathological myopia in Chinese patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 06 Dec 2015 New trial record